对司库奇尤单抗无应答的轴性脊柱关节炎患者1型干扰素特征增强
研究比较了30例轴性脊柱关节炎患者司库奇尤单抗治疗前及治疗24周后应答者与无应答者的免疫特征。无应答者治疗前IL-17A产生性RORγt+CD4+ T细胞频率较健康对照增高,且CXCR3+CD4+ T细胞较应答者显著增多;治疗后无应答者1型干扰素调节基因表达上调。
要点
- 司库奇尤单抗无应答者治疗前IL-17A产生性RORγt+CD4+ T细胞频率较健康对照增高(P < 0.01)。
- 无应答者治疗前CXCR3+CD4+ T细胞较应答者显著增多(P < 0.01)。
- 治疗后无应答者1型干扰素调节基因表达较应答者上调。
核心结论
- 无应答者IL-17A产生性细胞频率增高提示其炎症负荷高于应答者。
- 治疗后无应答者1型干扰素特征较应答者更明显,可能参与其较大炎症负荷的机制。
- 结果提示轴性脊柱关节炎的免疫异质性较既往认识更大,并凸显精准治疗的需求。
研究设计与样本
- 研究纳入30例轴性脊柱关节炎患者,在司库奇尤单抗治疗前及治疗24周后采集外周血单个核细胞。
- 采用流式细胞术比较应答者与无应答者之间CD4+亚群频率。
- 分选成熟CD45RO+CD45RA-CD4+ T细胞后,采用NanoString分析检测RNA。
主要发现
- 治疗前,无应答者IL-17A产生性RORγt+CD4+ T细胞频率较健康对照增高(P < 0.01)。
- 治疗前,无应答者CXCR3+CD4+ T细胞较应答者显著增多(P < 0.01)。
- 接受生物制剂治疗后,无应答者1型干扰素调节基因较应答者上调。
- 治疗前,应答者细胞毒性CD4+ T细胞基因特征较无应答者上调。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Axial spondyloarthritis (axSpA) is an inflammatory disease in which overactive interleukin (IL)-17A-producing cells are implicated in a central role. Therapeutically, biologics that target IL-17A, such as secukinumab, have demonstrated improved clinical outcomes. Despite this translational success, there is a gap in understanding why some patients with axSpA do not respond to IL-17A-blocking therapy. Our study aims to discriminate immune profiles between secukinumab responders (SEC-R) and nonresponders (SEC-NR). METHODS: Peripheral blood mononuclear cells were collected from 30 patients with axSpA before and 24 weeks after secukinumab treatment. Frequency of CD4+ subsets were compared between SEC-R and SEC-NR using flow cytometry. Mature CD45RO+CD45RA-CD4+ T cells were fluorescent-activated cell sorting sorted, and RNA was measured using NanoString analysis. RESULTS: SEC-NR had an increased frequency of IL-17A-producing RORγt+CD4+ T cells compared to healthy controls before secukinumab treatment (P < 0.01). SEC-NR had a significant increase of CXCR3+ CD4+ T cells before secukinumab treatment compared to SEC-R (P < 0.01). Differentially expressed gene analysis revealed up-regulation of type 1 interferon (IFN)-regulated genes in SEC-NR patients compared to SEC-R patients after receiving the biologic. SEC-R patients had an up-regulated cytotoxic CD4+ T cell gene signature before receiving secukinumab treatment compared to SEC-NR patients. CONCLUSION: The increased frequency of IL-17A-producing cells in SEC-NR patients suggests a larger inflammatory burden than SEC-R patients. With treatment, SEC-NR patients have a more pronounced type 1 IFN signature than SEC-R patients, suggesting a mechanism contributing to this larger inflammatory burden. The results point toward more immune heterogeneity in axSpA than has been recognized and highlights the need for precision therapeutics in this disease.
引用
- Pacheco A, Maguire S, Qaiyum Z, et al. Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment. Arthritis Rheumatol. 2024. PMID: 39160761. doi:10.1002/art.42974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。